LMY-920

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

What's the purpose of the trial?

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
30
Last Updated
10 months ago

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • LMY-920 is an autologous CAR-T cell therapy expressing the BAFF-ligand.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

LMY-920

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.